Motzer, R. J., McDermott, D. F., Escudier, B., Burotto, M., Choueiri, T. K., Hammers, H. J., . . . Tannir, N. M. (2022). Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 128(11), 2085-2097. https://doi.org/10.1002/cncr.34180
Chicago-Zitierstil (17. Ausg.)Motzer, Robert J., et al. "Conditional Survival and Long‐term Efficacy with Nivolumab Plus Ipilimumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma." Cancer 128, no. 11 (2022): 2085-2097. https://doi.org/10.1002/cncr.34180.
MLA-Zitierstil (9. Ausg.)Motzer, Robert J., et al. "Conditional Survival and Long‐term Efficacy with Nivolumab Plus Ipilimumab Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma." Cancer, vol. 128, no. 11, 2022, pp. 2085-2097, https://doi.org/10.1002/cncr.34180.